Investigating a key protein pathway in a rare liver cancer affecting young people

The role of DNAJB1-PKAc-β-catenin axis in fibrolamellar HCC

NIH-funded research Cincinnati Childrens Hosp Med Ctr · NIH-11054574

This study is looking into how a special protein linked to a rare liver cancer called Fibrolamellar Hepatocellular Carcinoma affects young people, with the hope of finding new ways to treat this condition.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionCincinnati Childrens Hosp Med Ctr NIH-funded
Lab location1 site (Cincinnati, United States)
Project IDNIH-11054574 on NIH RePORTER

What this research studies

This research focuses on understanding the cellular and molecular mechanisms behind Fibrolamellar Hepatocellular Carcinoma (FLC), a rare liver cancer that primarily affects children, adolescents, and young adults. The study examines how a specific fusion protein, DNAJB1-PKAc, contributes to the development of FLC by activating cancer-related genes through a pathway involving beta-catenin. Researchers will utilize both patient samples and animal models to explore this pathway and its implications for cancer progression. The goal is to identify potential therapeutic targets that could lead to better treatment options for affected patients.

Who could benefit from this research

Good fit: Ideal candidates for this research are children, adolescents, and young adults diagnosed with Fibrolamellar Hepatocellular Carcinoma.

Not a fit: Patients with other types of liver cancer or those with a history of liver disorders such as fibrosis or cirrhosis may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that specifically target the mechanisms driving Fibrolamellar Hepatocellular Carcinoma.

How similar studies have performed: Previous research has shown promising results in understanding the mechanisms of FLC, but this specific approach focusing on the DNAJB1-PKAc-beta-catenin axis is relatively novel.

Where this research is happening

Cincinnati, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions anti-cancer
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.